Literature DB >> 21793032

Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes.

Meital Gal-Tanamy1, Larisa Bachmetov, Amiram Ravid, Ruth Koren, Arie Erman, Ran Tur-Kaspa, Romy Zemel.   

Abstract

UNLABELLED: Vitamin D supplementation was reported to improve the probability of achieving a sustained virological response when combined with antiviral treatment against hepatitis C virus (HCV). Our aim was to determine the in vitro potential of vitamin D to inhibit HCV infectious virus production and explore the mechanism(s) of inhibition. Here we show that vitamin D(3) remarkably inhibits HCV production in Huh7.5 hepatoma cells. These cells express CYP27B1, the gene encoding for the enzyme responsible for the synthesis of the vitamin D hormonally active metabolite, calcitriol. Treatment with vitamin D(3) resulted in calcitriol production and induction of calcitriol target gene CYP24A1, indicating that these cells contain the full machinery for vitamin D metabolism and activity. Notably, treatment with calcitriol resulted in HCV inhibition. Collectively, these findings suggest that vitamin D(3) has an antiviral activity which is mediated by its active metabolite. This antiviral activity involves the induction of the interferon signaling pathway, resulting in expression of interferon-β and the interferon-stimulated gene, MxA. Intriguingly, HCV infection increased calcitriol production by inhibiting CYP24A1 induction, the enzyme responsible for the first step in calcitriol catabolism. Importantly, the combination of vitamin D(3) or calcitriol and interferon-α synergistically inhibited viral production.
CONCLUSION: This study demonstrates for the first time a direct antiviral effect of vitamin D in an in vitro infectious virus production system. It proposes an interplay between the hepatic vitamin D endocrine system and HCV, suggesting that vitamin D has a role as a natural antiviral mediator. Importantly, our study implies that vitamin D might have an interferon-sparing effect, thus improving antiviral treatment of HCV-infected patients.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21793032     DOI: 10.1002/hep.24575

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  63 in total

Review 1.  Immunology in the clinic review series; focus on type 1 diabetes and viruses: the innate immune response to enteroviruses and its possible role in regulating type 1 diabetes.

Authors:  K Lind; M H Hühn; M Flodström-Tullberg
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

2.  25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients.

Authors:  Arthur Belle; Emmanuel Gizard; Guillaume Conroy; Anthony Lopez; Magali Bouvier-Alias; Stéphanie Rouanet; Laurent Peyrin-Biroulet; Jean-Michel Pawlotsky; Jean-Pierre Bronowicki
Journal:  United European Gastroenterol J       Date:  2016-07-07       Impact factor: 4.623

3.  Suppression of iron-regulatory hepcidin by vitamin D.

Authors:  Justine Bacchetta; Joshua J Zaritsky; Jessica L Sea; Rene F Chun; Thomas S Lisse; Kathryn Zavala; Anjali Nayak; Katherine Wesseling-Perry; Mark Westerman; Bruce W Hollis; Isidro B Salusky; Martin Hewison
Journal:  J Am Soc Nephrol       Date:  2013-11-07       Impact factor: 10.121

Review 4.  Association between vitamin D and hepatitis C virus infection: a meta-analysis.

Authors:  Livia Melo Villar; José Antonio Del Campo; Isidora Ranchal; Elisabeth Lampe; Manuel Romero-Gomez
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

5.  Vitamin D status and viral response to therapy in hepatitis C infected children.

Authors:  Azza A Eltayeb; Madleen Adel A Abdou; Amal M Abdel-aal; Mostafa H Othman
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

6.  Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.

Authors:  Harel Dahari; Shimon Shteingart; Inna Gafanovich; Scott J Cotler; Massimo D'Amato; Ralf T Pohl; Gali Weiss; Yaakov J Ashkenazi; Thomas Tichler; Eran Goldin; Yoav Lurie
Journal:  Liver Int       Date:  2014-10-10       Impact factor: 5.828

7.  Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients.

Authors:  Saif Abu-Mouch; Zvi Fireman; Jacob Jarchovsky; Abdel-Rauf Zeina; Nimer Assy
Journal:  World J Gastroenterol       Date:  2011-12-21       Impact factor: 5.742

Review 8.  Complementary and alternative medications in hepatitis C infection.

Authors:  Dina L Halegoua-De Marzio; Jonathan M Fenkel
Journal:  World J Hepatol       Date:  2014-01-27

9.  Single-nucleotide polymorphism at CYP27B1-1260, but not VDR Taq I, is possibly associated with persistent hepatitis B virus infection.

Authors:  Qianqian Zhu; Na Li; Qunying Han; Zhu Li; Guoyu Zhang; Fang Li; Pingping Zhang; Jinghong Chen; Yi Lv; Zhengwen Liu
Journal:  Genet Test Mol Biomarkers       Date:  2012-09

10.  Vitamin D Metabolites Inhibit Hepatitis C Virus and Modulate Cellular Gene Expression.

Authors:  Julio A Gutierrez; Krysten A Jones; Roxana Flores; Akul Singhania; Christopher H Woelk; Robert T Schooley; David L Wyles
Journal:  J Virol Antivir Res       Date:  2014-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.